![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
984kB |
![[thumbnail of Supplementary Materials]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Materials)
485kB |
| Item Type: | Article |
|---|---|
| Title: | Anti-NMDA-receptor GluN1 antibody serostatus is robust in acute severe stroke |
| Creators Name: | Sperber, Pia Sophie, Hotter, Benjamin, Endres, Matthias, Prüss, Harald and Meisel, Andreas |
| Abstract: | BACKGROUND: Anti-N-methyl-D-aspartate IgM and IgA antibodies (NMDAR1-abs) are associated with unfavorable stroke outcomes and may be risk factors thereof. However, to utilize NMDAR1-abs serostatus for risk assessment in acute stroke, it is crucial to understand the robustness of serostatus during this phase. Therefore, we investigated the robustness of NMDAR1-abs serostatus and titer levels up to seven days after stroke. MTEHODS: In this exploratory analysis of the multicenter STRAWINSKI trial (identifier: NCT01264549), patients with severe ischemic stroke (NIHSS ≥ 9) in the middle cerebral artery territory were included. The first blood sample was taken within 36 h and then daily from day two to seven after stroke. NMDAR1-abs immunoglobulin (Ig)A and IgM were assessed in serum using cell-based assays. We initially measured NMDAR1-abs in the total cohort on day 1. Subsequently, in samples from seropositive and matched seronegative patients, we measured NMDAR1-abs on each following day. Titer dilutions started from 1:10 up to 1:1000. Seropositivity was defined as any titer > 0. RESULTS: Out of 171 patients (mean age = 76 [SD = 11], median NIHSS = 15 [IQR = 12–18]), 16 (9%) individuals were seropositive. Seropositive patients remained seropositive and matched seronegative participants remained seronegative over sequential measurements. Although titer levels remained largely unchanged, some patients showed fluctuating titers. CONCLUSIONS: The status of NMDAR1-abs seropositivity is stable during acute stroke, with little to no variation in titer levels. |
| Keywords: | Stroke, Antibodies, NMDA-Receptor, Biomarker |
| Source: | Diagnostics |
| ISSN: | 2075-4418 |
| Publisher: | MDPI |
| Volume: | 15 |
| Number: | 24 |
| Page Range: | 3132 |
| Date: | 9 December 2025 |
| Official Publication: | https://doi.org/10.3390/diagnostics15243132 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
